LeMaitre initiated with an Equal Weight at Wells Fargo

Wells Fargo analyst Nathan Treybeck initiated coverage of LeMaitre (LMAT) with an Equal Weight rating and $95 price target The firm believes the company’s high-single-digit pricing contribution to 2025 organic growth is already priced into the stock. LeMaitre is a leading player in several niche open vascular surgery markets, but the shares offer limited upside from current levels, the analyst tells investors in a research note. Wells says a key debate in the stock is how long the recent price floor adjustments can sustain above-historical pricing growth.